Dantrolene-13C3 structure
|
Common Name | Dantrolene-13C3 | ||
---|---|---|---|---|
CAS Number | 1185234-99-4 | Molecular Weight | 317.23100 | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | C14H10N4O5 | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of Dantrolene-13C3Dantrolene-13C3 is the 13C3 labeled Dantrolene. Dantrolene (F368), a muscle relaxant, non-competitively inhibits human erythrocyte glutathione reductase. Ki and IC50 values are 111.6 μM and 52.3 μM, respectively. Dantrolene is a ryanodine receptor antagonist and Ca2+ signaling stabilizer. Dantrolene can be used for the research of muscle spasticity, malignant hyperthermia, Huntington's disease and other neuroleptic malignant syndrome. |
Name | Dantrolene-13C3 |
---|---|
Synonym | More Synonyms |
Description | Dantrolene-13C3 is the 13C3 labeled Dantrolene. Dantrolene (F368), a muscle relaxant, non-competitively inhibits human erythrocyte glutathione reductase. Ki and IC50 values are 111.6 μM and 52.3 μM, respectively. Dantrolene is a ryanodine receptor antagonist and Ca2+ signaling stabilizer. Dantrolene can be used for the research of muscle spasticity, malignant hyperthermia, Huntington's disease and other neuroleptic malignant syndrome. |
---|---|
Related Catalog | |
In Vitro | Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1]. |
References |
Molecular Formula | C14H10N4O5 |
---|---|
Molecular Weight | 317.23100 |
Exact Mass | 317.07500 |
PSA | 124.22000 |
LogP | 2.47750 |
1-[(E)-[5-(4-nitrophenyl)furan-2-yl]methylideneamino]imidazolidine-2,4-dione-13C3 |